Cytovation ASACytovation ASA has baged US$6m to advance Phase II development of its bi-specific pore-forming peptide candidate CY-101 in patients with adrenocortical carcinoma.
ADVERTISEMENT
Cytovation ASA has baged US$6m to advance Phase II development of its bi-specific pore-forming peptide candidate CY-101 in patients with adrenocortical carcinoma.